THE WOODLANDS, Texas, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the company will host a virtual webcast: “LX9211 - Changing the Paradigm for ...
Rapport Therapeutics Inc (Rapport Therapeutics), is a biotechnology company that focused on discovery and development of precision therapies, treatment for neurological disorders, clinical trails, ...
Deuterated etifoxine is under clinical development by GABA Therapeutics and currently in Phase I for Neuropathic Pain (Neuralgia). According to GlobalData, Phase I drugs for Neuropathic Pain ...